Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020198323 - PRMT5 INHIBITORS AND USES THEREOF

Publication Number WO/2020/198323
Publication Date 01.10.2020
International Application No. PCT/US2020/024654
International Filing Date 25.03.2020
IPC
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 519/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
519Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/ or C07D455/257
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/52 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
Applicants
  • CALIFORNIA INSTITUTE OF TECHNOLOGY [US]/[US]
  • 1200 PHARMA LLC
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • O'BOYLE, Brendan, M.
  • REEVES, Corey, M.
  • HILF, Justin, A.
  • STOLTZ, Brian, M.
  • BARTBERGER, Michael, D.
  • WITTENBERGER, Steven, J.
  • LOSON, Oliver, C.
  • MCDERMOTT, Martina, S.
  • O'BRIEN, Neil, A.
  • SLAMON, Dennis
Agents
  • LADISHAW, Janine, S.
  • CAI, Mi
  • CAO, Yichen
  • AKHIEZER, Alexander
  • ABELLEIRA, Susan, M.
Priority Data
62/823,37425.03.2019US
62/874,77316.07.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PRMT5 INHIBITORS AND USES THEREOF
(FR) INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
Abstract
(EN)
The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
(FR)
La présente invention concerne des composés de formules (I)- (V) et leurs procédés de fabrication. Les composés de la présente invention sont utiles en tant qu'inhibiteurs de l'activité de PRMT5 et dans des méthodes de traitement de cancers et d'autres maladies.
Latest bibliographic data on file with the International Bureau